Civitelli, Diego

Number of items: 8.
2026
  • Candore, Gianmario, Martin, Claire, Mills, Mackenzie J., Suter, Annabel, Lloyd, Anna, Chavez‐Montoya, Danitza, Civitelli, Diego, Wolf, Birgit, Bolot, Paul & Wasem, Juergen et al (2026). Reply to "On selection and analytical transparency in the FRAME Framework for RWE evaluation". Clinical Pharmacology and Therapeutics, https://doi.org/10.1002/cpt.70197
    • 2025
  • Civitelli, Diego, Kanavos, Panos (2025). HPR2 A case study: how England implemented its first Population Health Agreement. Value in Health, 28(12, Supplement 1), S321. https://doi.org/10.1016/j.jval.2025.09.1412
  • Civitelli, Diego, Therianos, Panagiotis, Gill, Jennifer, Kanavos, Panos (2025). HTA222 Life-years lost due to regulatory and reimbursement delays: a study of oncology drugs across England, Scotland, and France, 2022-2024. Value in Health, 28(12, Supplement 1), S448. https://doi.org/10.1016/j.jval.2025.09.2006
  • Candore, Gianmario, Martin, Claire, Mills, Mack J., Suter, Annabel, Lloyd, Anna, Chavez‐Montoya, Danitza, Civitelli, Diego, Wolf, Birgit, Bolot, Paul & Wasem, Juergen et al (2025). FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence uncertainties for efficacy/effectiveness – an evaluation of regulatory and health technology assessment decision making. Clinical Pharmacology and Therapeutics, 118(3), 649 - 661. https://doi.org/10.1002/cpt.3713 picture_as_pdf
  • Civitelli, Diego, Satish, Kavyashree, Kanavos, Panos (2025). HSD8 A case-study on the implementation of the Population Health Agreement for Inclisiran in England. Value in Health, 28(6, Supplement 1), S226. https://doi.org/10.1016/j.jval.2025.04.904
  • Civitelli, Diego, Mills, Mackenzie, Kanavos, Panos (2025). HTA69 A retrospective analysis of the Italian Medicines Agency’s evaluation of real-world evidence in innovativeness assessments. Value in Health, 28(6, Supplement 1), S259. https://doi.org/10.1016/j.jval.2025.04.1080
    • 2024
  • Civitelli, D., Politopoulou, K., Mills, Mackenzie, Kanavos, P. (2024). HTA18 First to launch, first to falter?: an investigation into the clinical benefits and HTA outcomes for first-in-class drugs. Value in Health, 27(12, Supplement), S356 - S356. https://doi.org/10.1016/j.jval.2024.10.1843
  • Candore, Gianmario, Martin, Claire, Gabarro, Montse Soriano, Mills, Mackenzie, Kanavos, Panos, Bromley, Susan, Cooper, Amy L., Wolf, Birgit, Bolot, Paul & Franklin, Joe et al (2024). Drivers and methodological considerations associated with the acceptability of real-world evidence for effectiveness/efficacy by regulators and HTAs: evidence from North America, Europe, and Australia. Pharmacoepidemiology and Drug Safety, 33, 542 - 543. https://doi.org/10.1002/pds.5891